ImmuCell Corporation
corporate_fare Company Profile
ImmuCell Corporation (NASDAQ:ICCC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ICCC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for ICCC spans 10-Q, 8-K, DEF 14A, PRE 14A.
Recent high-impact activity:
- ImmuCell Q3 Net Income $953K as Sales Jump 46%; Cash Nearly Doubles to $7.9M
- ImmuCell Swings to $953K Profit as Q3 Revenue Jumps 46% to $8.0M
- ImmuCell Q3 Sales Jump 46% to $8M on Broad Product Growth
- ImmuCell Q2 Net Income Hits $1.8M on Legal Settlement, Plans $8M Capacity Expansion
- ImmuCell Q2 Net Income Soars 266% on $2M Settlement and Strong Sales
Financial Snapshot
Short Interest & Short Volume
2.79 days to coverFINRA reported short interest of 14,706 shares in ICCC as of the October 30, 2026 settlement, a 18.8% decrease from the prior period — about 2.8 days to cover at its recent average daily volume. On November 20, 2026, 40.6% of ICCC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.